RxDoctor Payments Data

Lawrence Mahdi, MD

Cardiovascular Disease · Bloomfield, NJNPI 1689607103

Payments from drug & device makers

$1,465in general payments, 2019–2025

Across 101 payments — averaging $14.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$292
  • Amgen$217
  • Amarin Pharma, Inc.$158
  • Boston Scientific$113
  • AstraZeneca$91
  • Pfizer$90
  • plus $504 from 14 others

What the payments were for

  • Food & beverage$1,465100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,465 in reported general payments places this provider in the 35th percentile of 1,006 cardiovascular disease providers in New Jersey.

See all cardiovascular disease providers in New Jersey

Medicare billing

Part B allowed, 2024
$388,390
Medicare patients
735
Services billed
5,344

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban240$290,256
EntrestoSacubitril/Valsartan122$172,193
XareltoRivaroxaban91$124,086
Repatha SureclickEvolocumab100$119,111
VascepaIcosapent Ethyl67$43,749
FarxigaDapagliflozin Propanediol27$36,231
Praluent PenAlirocumab45$35,213
MultaqDronedarone Hcl19$25,979
BrilintaTicagrelor19$19,083
Ezetimibe394$12,881
NexletolBempedoic Acid19$12,404
Rosuvastatin Calcium610$12,150
EdarbiAzilsartan Medoxomil14$11,531
Icosapent Ethyl19$9,173
CrestorRosuvastatin Calcium13$8,642

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$90$290,256240 claims
NovartisEntresto$292$172,193122 claims
Johnson & JohnsonXarelto$53$124,08691 claims
AstraZenecaFarxiga, Brilinta, Crestor$91$63,95659 claims
Sanofi-aventis U.S. LLCMultaq$27$25,97919 claims
Arbor Pharmaceuticals, Inc.Edarbi, Edarbyclor$37$16,27828 claims
Esperion Therapeutics, Inc.Nexletol$49$12,40419 claims
Kowa Pharmaceuticals America, Inc.Livalo, Bystolic$50$12,16824 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 1,006 cardiovascular disease providers in New Jersey.

Other cardiovascular disease in Bloomfield

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →